Home
Clinical Trials
Efficacy and Safety of Everol...

Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants

Last Updated: 2019-03-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

285 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-25

Study Completion Date

2018-04-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial was to demonstrate the efficacy and safety of everolimus in combination with reduced tacrolimus, compared to tacrolimus control, in living donor liver transplant recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients

NCT01551212

Liver Transplantation

COMPLETED PHASE4

Everolimus Post Orthotopic Liver Transplant

NCT01998789

Orthotopic Liver Transplant

UNKNOWN PHASE2

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869

Liver Transplantation

COMPLETED PHASE3

EVR and EPO for Liver Transplant Tolerance

NCT06832189

Liver Transplant

RECRUITING PHASE1

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

NCT06280950

Liver Transplant

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was 24 month, multicenter study in 280 living donor liver transplant patients from Asia, Europe and Canada. The study has an long term extension in Japan and approximately 28 patients were to be included to evaluate the long-term efficacy and safety of concentration-controlled everolimus regimen plus reduced tacrolimus compared to standard tacrolimus in recipients of living donor liver transplants in Japan who participated in the CRAD001H2307 study.

Data reported here are the CRAD001H2307 core study results and its extension (CRAD001H2307E1).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This was a 24-month, multicenter, open-label, randomized, controlled study. It included the extension to the 24-month, randomized, controlled, open-label CRAD001H2307 study in recipients of living donor liver transplants in Japan.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Everolimus + reduced tacrolimus

Everolimus + reduced tacrolimus ± corticosteroids

Group Type EXPERIMENTAL

Everolimus + reduced tacrolimus

Intervention Type DRUG

Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.

Standard tacrolimus

Standard tacrolimus ± corticosteroids

Group Type ACTIVE_COMPARATOR

Standard tacrolimus

Intervention Type DRUG

Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Everolimus + reduced tacrolimus

Intervention Type DRUG

Standard tacrolimus

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Subject aged ≥18 years of a primary, orthotopic liver allograft, from a living donor
* Subject negative for HIV

Incusion criteria at Randomization:

\- Subject was initated on tacrolimus-based immunosuppressive regimen with steroids and other immunosuppression

* Written informed consent must be obtained before any extension specific assessment is performed.
* Ability and willingness to adhere to study regimen.
* Completed Month 24 visit of core study and continuously being treated with assigned regimen.

Exclusion Criteria

* Subjects transplanted for acute liver failure
* HCV negativesubjects receiving a transplant from HCV positive donor
* Subjects receiving multiple solid organ (including multiple liver lobes/segments) or islet cell tissue transplants, or have previously received an organ or tissue transplant.
* Subjects receiving an ABO incompatible allograft.
* MELD-score \> 35 within 1 month prior to transplantation.
* Use of immunosuppressive or antibody induction agents not specified in the protocol.
* History of malignancy of any organ system (except hepatocellular carcinoma or localized basal cell carcinoma of the skin)
* Hepatocellular carcinoma with extrahepatic spread or macrovascular invasion
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 2 weeks after the last dose of study medication
* History of hypersensitivity to any of the study drugs or to drugs with similar chemical class, or to any of the excipients

* Any post-transplant history of thrombosis, occlusion or stent placement in any major hepatic arteries, hepatic veins, portal vein or inferior vena cava at any time during the run-in period prior to randomization.
* Subjects with a confirmed spot urine protein/creatinine ratio that indicates ≥ 1.0 g/24 hrs of proteinuria
* Subjects who have severe hypercholesterolemia (\>350 mg/dL; \>9.1 mmol/L) or hypertriglyceridemia (\>500 mg/dL; \>5.6 mmol/L) at randomization.
* Subjects with platelet count \< 30,000/mm3.
* Subjects with an absolute neutrophil count of \< 1,000/mm³ or white blood cell count of \< 2,000/mm³.
* Subjects with systemic infection requiring active use of IV antibiotics.
* Subjects requiring life support measures such as ventilation, dialysis, vasopressor agents.
* Subjects who require renal replacement therapy within 7 days prior to randomization.
* Subjects with detectable HBV DNA at time of randomization
* Subjects meeting the following criteria for acute rejection during the run in period:

* Any acute rejection in the week prior to randomization.
* 2 treated acute rejections.
* Any rejection requiring antibody treatment.
* Any severe cellular (and/or any humoral) rejection.

Long term extension for patients in Japan:

* Use of medication that is prohibited by the study protocol at Month 24.
* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
* History of hypersensitivity to any of the study drugs or to drugs with similar chemical class, or to any of the excipients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers